Biomodal

Executive Summary

Biomodal is a UK-based biotechnology company founded in 2019 that has developed a proprietary multiomic analysis platform capable of capturing both genetic and epigenetic information from a single DNA sample in a single workflow. This integrated approach provides a more comprehensive view of biology than traditional methods, making it particularly promising for applications in cancer, neurodegenerative disease, and precision medicine. By combining genomics and epigenomics, Biomodal’s technology aims to uncover novel biomarkers and disease mechanisms that may be missed by conventional sequencing. The company's platform is positioned to accelerate research and drug development, potentially enabling earlier diagnosis and better patient stratification. Given its innovative technology and focus on high-impact disease areas, Biomodal represents a compelling opportunity in the multiomics space.

Upcoming Catalysts (preview)

• Q4 2026Series B funding round to support platform commercialization75% success
• Q2 2027Pharmaceutical partnership for oncology biomarker discovery60% success
• Q1 2027Launch of first commercial multiomic assay for research use65% success